^
    Back
    Association details:
    Biomarker:HLA-A*02
    Cancer:Solid Tumor
    Drug:SQZ-AAC-HPV (Immunomodulator)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

    Excerpt:
    ...- Male or female patients ≥18 years of age who are HLA-A*02+ (performed during screening locally or centrally, or based on documented historic test results)...
    Trial ID:
    ENVOY-001
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SITC 2023
    Title:

    693 SQZ-AAC-HPV-101: initial data from a phase I dose escalation/expansion study of SQZ-AAC-HPV, a red blood cell-based therapeutic cancer vaccine for HPV16+ solid tumors

    Published date:
    11/04/2023
    Excerpt:
    SQZ-AAC-HPV-101 (NCT04892043) enrolled HLA-A*02+patients with advanced HPV16+ cancers...Three patients in the low dose cohort have undergone at least one on-treatment scan; two patients showed a best overall response of stable disease...SQZ-AAC-HPV treatment was generally well-tolerated and initial efficacy data are encouraging.
    DOI:
    http://dx.doi.org/10.1136/jitc-2023-SITC2023.0693
    Trial ID:
    ENVOY-001